Serum posaconazole levels during acute myeloid leukaemia induction therapy: Correlations with breakthrough invasive fungal infections

Mycoses

Volumn 58, Issue 6, 2015, Pages 362-367

  Cattaneo, Chiara ^a   Panzali, Annafranca ^a   Passi, Angela ^a   Borlenghi, Erika ^a   Lamorgese, Cinzia ^a   Petullà, Marta ^a   Re, Alessandro ^a   Caimi, Luigi ^a,b   Rossi, Giuseppe ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute leukaemia; Invasive fungal infections; Posaconazole prophylaxis; Therapeutic drug monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; POSACONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANTIFUNGAL THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; CANDIDEMIA; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; ADOLESCENT; AGED; CHEMISTRY; COMPLICATION; FUNGEMIA; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; SERUM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; FUNGEMIA; HUMANS; INCIDENCE; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SERUM; TRIAZOLES; YOUNG ADULT;

EID: 84929452717     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12326     Document Type: Article

References (32)

1. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
2. Even C, Bastuji-Garin S, Hicheri Y et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. Haematologica 2011; 96: 337-41.
3. Michallet M, Bénet T, Sobh M et al. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis 2012; 31: 991-7.
4. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
5. Ananda-Rajah MR, Grigg A, Downey MT et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukaemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012; 97: 459-63.
6. Girmenia C, Frustaci AM, Gentile G et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 2012; 97: 560-7.
7. Vehreschild JJ, Rüping MJ, Wisplinghoff H et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65: 1466-71.
8. Pagano L, Caira M, Candoni A et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis 2012; 55: 1515-21.
9. Lipp HP. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol 2010; 70: 471-80.
10. Vehreschild JJ, Müller C, Farowski F et al. Factors influencing pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol 2012; 68: 987-95.
11. Kohl V, Müller C, Cornely OA et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010; 54: 207-12.
12. Cornely OA, Helfgott D, Langston A et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother 2012; 56: 2652-8.
13. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
14. Pascual A, Csajka C, Buclin T et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 55: 381-90.
15. Lebeaux D, Lanternier F, Elie C et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53: 5224-9.
16. Neubauer WC, Engelhardt M, König A et al. Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother 2010; 54: 4029-32.
17. Eiden C, Meniane JC, Peyrière H et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis 2012; 31: 161-7.
18. Hoenigl M, Raggam RB, Salzer HJ et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012; 39: 510-3.
19. Dolton MJ, Ray JE, Chen SC et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56: 4793-9.
20. Gross BN, Ihorst G, Jung M, Wäsch R, Engelhardt M. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy 2013; 33: 1117-25.
21. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
22. Jang SH, Colangelo PM, Gobburu JVS. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115-9.
23. Intermesoli T, Rossi G, Pogliani E et al. Two-step response-oriented induction predicts long-term outcome of adult patients with standard and high-risk acute myeloid leukaemia (AML): a Northern Italy Leukaemia Group (NILG) study. In: Haematologica (ed), Abstracts of the Fifteenth EHA Annual Meeting. Barcelona, Spain: European Hematology Association, 2010; 95(s2): 272; Abstract 649.
24. Lo Coco F, Avvisati G, Vignetti M et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; 116: 3171-9.
25. de Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
26. Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug monitoring: a practical approach. Curr Opin Infect Dis 2012; 25: 606-11.
27. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.
28. Cojutti P, Candoni A, Simeone E, Franceschi L, Fanin R, Pea F. Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. Antimicrob Agents Chemother 2013; 57: 6081-4.
29. Hummert SE, Green MR. Therapeutic drug monitoring and dose adjustment of posaconazole oral suspension in adults with acute myeloid leukemia. Ther Drug Monit 2014; doi:10.1097/FTD.0000000000000175. Epub ahead of print.
30. Campoli P, Al Abdallah Q, Robitaille R et al. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother 2011; 55: 5732-9.
31. Farowski F, Cornely OA, Vehreschild JJ et al. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother 2010; 54: 2928-31.
32. Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 2014; 58: 4020-5.